Evidence for the ISG15-Specific Deubiquitinase USP18 as an Antineoplastic Target.
暂无分享,去创建一个
E. Dmitrovsky | L. Mustachio | J. Roszik | S. Freemantle | Xi Liu | Yun Lu | M. Kawakami | Masanori Kawakami
[1] E. Dmitrovsky,et al. Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer , 2017, Molecular Cancer Research.
[2] K. Knobeloch,et al. Structural basis of the specificity of USP18 toward ISG15 , 2017, Nature Structural &Molecular Biology.
[3] Jun Yu,et al. The ISG15-specific protease USP18 regulates stability of PTEN , 2016, Oncotarget.
[4] Dong-er Zhang,et al. Multiple functions of USP18 , 2016, Cell Death & Disease.
[5] X. Mao,et al. Interferon-stimulated gene 15 induces cancer cell death by suppressing the NF-κB signaling pathway , 2016, Oncotarget.
[6] S. Pierrou,et al. The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells , 2016, Scientific Reports.
[7] Xiaodong Huang,et al. Drugging the undruggables: exploring the ubiquitin system for drug development , 2016, Cell Research.
[8] M. Beckmann,et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses , 2016, Cell.
[9] E. Dmitrovsky,et al. Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas , 2015, BMC Cancer.
[10] Q. Dou,et al. Deubiquitinases (DUBs) and DUB inhibitors: a patent review , 2015, Expert opinion on therapeutic patents.
[11] S. Desai. ISG15: A double edged sword in cancer , 2015, Oncoimmunology.
[12] S. Linder,et al. Deubiquitinase inhibition as a cancer therapeutic strategy. , 2015, Pharmacology & therapeutics.
[13] V. Saridakis,et al. Deubiquitinases and the new therapeutic opportunities offered to cancer , 2015, Endocrine-related cancer.
[14] K. Knobeloch,et al. Selective inactivation of USP18 isopeptidase activity in vivo enhances ISG15 conjugation and viral resistance , 2015, Proceedings of the National Academy of Sciences.
[15] Hong Zhang,et al. Interferon-stimulated Gene 15 (ISG15) is a trigger for tumorigenesis and metastasis of hepatocellular carcinoma , 2014, Oncotarget.
[16] Yuhuan Zheng,et al. USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity , 2014, Molecular Cancer.
[17] D. Lane,et al. Isg15 controls p53 stability and functions , 2014, Cell cycle.
[18] G. Stark,et al. Interferons and their stimulated genes in the tumor microenvironment. , 2014, Seminars in oncology.
[19] Yung-Hyun Choi,et al. Novel Combination Markers for Predicting Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2 , 2014, Journal of Korean medical science.
[20] S. Desai,et al. ISGylation governs the oncogenic function of Ki-Ras in breast cancer , 2014, Oncogene.
[21] C. Brancolini,et al. The DeISGylase USP18 limits TRAIL-induced apoptosis through the regulation of TRAIL levels , 2013, Cancer biology & therapy.
[22] Q. Dou,et al. Targeting the ubiquitin–proteasome system for cancer therapy , 2013, Expert opinion on therapeutic targets.
[23] K. Yui. Cross-presentation of malaria antigen by brain microvessels: why CD8+ T cells are critical for the pathogenesis of experimental cerebral malaria , 2013, EMBO molecular medicine.
[24] S. Kotenko,et al. Usp18 deficient mammary epithelial cells create an antitumour environment driven by hypersensitivity to IFN-λ and elevated secretion of Cxcl10 , 2013, EMBO molecular medicine.
[25] V. Huff,et al. Ubiquitin specific protease 18 (Usp18) is a WT1 transcriptional target. , 2013, Experimental cell research.
[26] P. Marchetti,et al. USP18 is a key regulator of the interferon-driven gene network modulating pancreatic beta cell inflammation and apoptosis , 2012, Cell Death and Disease.
[27] E. Dmitrovsky,et al. Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target , 2012, Molecular Cancer Therapeutics.
[28] Ming Yan,et al. Usp18 Promotes Conventional CD11b+ Dendritic Cell Development , 2012, The Journal of Immunology.
[29] V. Quesada,et al. Deubiquitinases in cancer: new functions and therapeutic options , 2012, Oncogene.
[30] S. Pellegrini,et al. USP18-Based Negative Feedback Control Is Induced by Type I and Type III Interferons and Specifically Inactivates Interferon α Response , 2011, PloS one.
[31] A. Sorkin,et al. Usp18 Regulates Epidermal Growth Factor (EGF) Receptor Expression and Cancer Cell Survival via MicroRNA-7* , 2011, The Journal of Biological Chemistry.
[32] Dong-er Zhang,et al. Interferon-stimulated gene 15 and the protein ISGylation system. , 2011, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[33] E. Dmitrovsky,et al. Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARα and inhibits the growth of acute promyelocytic leukemia. , 2010, Cancer research.
[34] B. Sarcevic,et al. Mechanisms of mono- and poly-ubiquitination: Ubiquitination specificity depends on compatibility between the E2 catalytic core and amino acid residues proximal to the lysine , 2010, Cell Division.
[35] C. Brancolini,et al. Identification of USP18 as an important regulator of the susceptibility to IFN-alpha and drug-induced apoptosis. , 2010, Cancer research.
[36] Michael J. Clague,et al. Emerging roles of deubiquitinases in cancer‐associated pathways , 2010, IUBMB life.
[37] David Komander,et al. Breaking the chains: structure and function of the deubiquitinases , 2009, Nature Reviews Molecular Cell Biology.
[38] E. Dmitrovsky,et al. UBE1L causes lung cancer growth suppression by targeting cyclin D1 , 2008, Molecular Cancer Therapeutics.
[39] Dong-er Zhang,et al. ISG15 Inhibits Nedd4 Ubiquitin E3 Activity and Enhances the Innate Antiviral Response*♦ , 2008, Journal of Biological Chemistry.
[40] S. Kitareewan,et al. UBE1L represses PML/RARα by targeting the PML domain for ISG15ylation , 2008, Molecular Cancer Therapeutics.
[41] Ming Yan,et al. Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signaling. , 2007, Blood.
[42] Michalis V. Karamouzis,et al. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets , 2007, Nature Reviews Drug Discovery.
[43] Ming Yan,et al. Microarray analysis reveals that Type I interferon strongly increases the expression of immune-response related genes in Ubp43 (Usp18) deficient macrophages. , 2007, Biochemical and biophysical research communications.
[44] Sudhir Srivastava,et al. Posttranslational Protein Modifications , 2006, Molecular & Cellular Proteomics.
[45] K. Shuai,et al. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity , 2006, The EMBO journal.
[46] S. Kitareewan,et al. Retinoid target genes in acute promyelocytic leukemia , 2003, Leukemia.
[47] Dong-er Zhang,et al. UBP43 (USP18) Specifically Removes ISG15 from Conjugated Proteins* , 2002, The Journal of Biological Chemistry.
[48] D. Zhang,et al. Cloning and characterization of a novel human ubiquitin-specific protease, a homologue of murine UBP43 (Usp18). , 2000, Genomics.
[49] A. Iwama,et al. A Novel Ubiquitin-Specific Protease, UBP43, Cloned from Leukemia Fusion Protein AML1-ETO-Expressing Mice, Functions in Hematopoietic Cell Differentiation , 1999, Molecular and Cellular Biology.
[50] Aaron Ciechanover,et al. The ubiquitin-proteasome proteolytic pathway , 1994, Cell.